169 related articles for article (PubMed ID: 31916505)
1. Virtual screening, molecular dynamics, density functional theory and quantitative structure activity relationship studies to design peroxisome proliferator-activated receptor-γ agonists as anti-diabetic drugs.
Ahmed S; Islam N; Shahinozzaman M; Fakayode SO; Afrin N; Halim MA
J Biomol Struct Dyn; 2021 Feb; 39(2):728-742. PubMed ID: 31916505
[TBL] [Abstract][Full Text] [Related]
2. Study of new interactions of glitazone's stereoisomers and the endogenous ligand 15d-PGJ2 on six different PPAR gamma proteins.
Álvarez-Almazán S; Bello M; Tamay-Cach F; Martínez-Archundia M; Alemán-González-Duhart D; Correa-Basurto J; Mendieta-Wejebe JE
Biochem Pharmacol; 2017 Oct; 142():168-193. PubMed ID: 28716729
[TBL] [Abstract][Full Text] [Related]
3. Virtual identification of novel PPARα/γ dual agonists by 3D-QSAR, molecule docking and molecular dynamics studies.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
J Biomol Struct Dyn; 2020 Jun; 38(9):2672-2685. PubMed ID: 31418313
[TBL] [Abstract][Full Text] [Related]
4. In silico identification of potential drug compound against Peroxisome proliferator-activated receptor-gamma by virtual screening and toxicity studies for the treatment of Diabetic Nephropathy.
Singh S; Mohanty A
J Biomol Struct Dyn; 2018 May; 36(7):1776-1787. PubMed ID: 28539091
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel peroxisome proliferator-activated receptor-gamma (PPARγ) agonists using molecular modeling method.
Gee VM; Wong FS; Ramachandran L; Sethi G; Kumar AP; Yap CW
J Comput Aided Mol Des; 2014 Nov; 28(11):1143-51. PubMed ID: 25168706
[TBL] [Abstract][Full Text] [Related]
6. Structure based docking and molecular dynamics studies: Peroxisome proliferator-activated receptors -α/γ dual agonists for treatment of metabolic disorders.
Nath V; Agrawal R; Kumar V
J Biomol Struct Dyn; 2020 Feb; 38(2):511-523. PubMed ID: 30767625
[TBL] [Abstract][Full Text] [Related]
7. Oxadiazolyl thiazolidinedione as a non-adipogenic PPAR-γ partial agonist and its effect on glucose homeostasis in type 2 diabetes.
Thangavel N; Bratty MA; Javed SA; Ahsan W; Hazmi HA
J Biol Regul Homeost Agents; 2019; 33(3):707-719. PubMed ID: 31204468
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations.
Liu X; Jing Z; Jia WQ; Wang SQ; Ma Y; Xu WR; Liu JW; Cheng XC
J Biomol Struct Dyn; 2018 Aug; 36(11):2988-3002. PubMed ID: 28853334
[TBL] [Abstract][Full Text] [Related]
9.
Feng XY; Ding TT; Liu YY; Xu WR; Cheng XC
J Biomol Struct Dyn; 2021 Mar; 39(5):1853-1864. PubMed ID: 32189570
[TBL] [Abstract][Full Text] [Related]
10. Computational investigation of phytochemicals from
Omoboyowa DA; Singh G; Fatoki JO; Oyeneyin OE
J Biomol Struct Dyn; 2023; 41(12):5568-5582. PubMed ID: 35773777
[TBL] [Abstract][Full Text] [Related]
11. Structure-based identification of novel PPAR gamma ligands.
da Silva FM; dos Santos JC; Campos JL; Mafud AC; Polikarpov I; Figueira AC; Nascimento AS
Bioorg Med Chem Lett; 2013 Nov; 23(21):5795-802. PubMed ID: 24075729
[TBL] [Abstract][Full Text] [Related]
12. Citrus nutraceutical eriocitrin and its metabolites are partial agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a molecular docking and molecular dynamics study.
Gangadhariah M; Pardhi T; Ravilla J; Chandra S; Singh SA
J Biomol Struct Dyn; 2023; 41(21):11373-11393. PubMed ID: 36576222
[TBL] [Abstract][Full Text] [Related]
13. Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study.
Salam NK; Huang TH; Kota BP; Kim MS; Li Y; Hibbs DE
Chem Biol Drug Des; 2008 Jan; 71(1):57-70. PubMed ID: 18086153
[TBL] [Abstract][Full Text] [Related]
14. Identification of Potential PPAR γ Agonists as Hypoglycemic Agents: Molecular Docking Approach.
Mishra GP; Sharma R
Interdiscip Sci; 2016 Sep; 8(3):220-8. PubMed ID: 26374652
[TBL] [Abstract][Full Text] [Related]
15. Exploring Dual Agonists for PPARα/γ Receptors using Pharmacophore Modeling, Docking Analysis and Molecule Dynamics Simulation.
Ding TT; Liu YY; Zhang LM; Shi JR; Xu WR; Li SY; Cheng XC
Comb Chem High Throughput Screen; 2022; 25(9):1450-1461. PubMed ID: 34182904
[TBL] [Abstract][Full Text] [Related]
16. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
Chen R; Wan J; Song J; Qian Y; Liu Y; Gu S
Pharm Biol; 2017 Dec; 55(1):503-509. PubMed ID: 27937122
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists.
Kaserer T; Obermoser V; Weninger A; Gust R; Schuster D
Eur J Med Chem; 2016 Nov; 124():49-62. PubMed ID: 27560282
[TBL] [Abstract][Full Text] [Related]
18. Uncovering PPAR-γ agonists: An integrated computational approach driven by machine learning.
Haider S; Shafiq M; Siddiqui AR; Sardar M; Mushtaq M; Shafeeq S; Nur-E-Alam M; Ahmad A; Ul-Haq Z
J Mol Graph Model; 2024 Jun; 129():108742. PubMed ID: 38422823
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.
Bergeron R; Yao J; Woods JW; Zycband EI; Liu C; Li Z; Adams A; Berger JP; Zhang BB; Moller DE; Doebber TW
Endocrinology; 2006 Sep; 147(9):4252-62. PubMed ID: 16728496
[TBL] [Abstract][Full Text] [Related]
20. Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists using 3D-QSAR and Molecular Docking.
Jian Y; He Y; Yang J; Han W; Zhai X; Zhao Y; Li Y
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29473866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
